Drugs Made In America Acquisition Corp. (DMAA)

$DMAA ....This "pending" S-1 should be interesting....$300M floor is potentiaaly a nice touch from the $1B 'headline'...just musing about..slowly peeling back the onion...glta "When Will Verifiable Financials Become Available?To legally complete this merger, DMAA must file a formal, detailed S-4 or Proxy Statement with the SEC. By law, that specific filing must contain audited Balance Sheets and Income Statements for PAGC covering at least the last two fiscal years." "Historical Restructuring and Asset SalesPAGC's technology foundation stems from an older company (Power Analytics Corp) that historically went through extensive litigation and restructuring. In 2019, specific core intellectual property and operational assets of the business were bought out by WaveTech Global in an all-stock equity transaction rather than a cash buyout, but it has only recently pivoted into its current model as an AI, machine learning, and quantum-resistant data security solution provider.

$DMAA . Gemini taking a peek... "Quantum Computing Inc. (QCI) Litigation: In 2022, BV Advisory sued QCI and QPhoton, alleging breaches of fiduciary duty, breached contracts, and fraudulent transfer following QCI's acquis of QPhoton. BV Advisory claimed it was owed millions in cash and significant equity as an early inv. and negotiator for QPhoton. Countersuits & Defamation: In response, QCI countersued Barksdale and BV Advisory, accusing them of a years-long scheme of misrepresentation, defamation, and intimidation. Resolution: The long-running, multi-claim, multi-court disputes between the entities came to an end. Barksdale, BV Advisory, and QCI ultimately signed a confidential settlement agree, which fully resolved their disputes and resulted in the dismissal of all litigation between them. Gen'l Contract & Labor Disputes: Barksdale and BV Adv have also faced other distinct civil actions, including a 2019 wage and breach-of-contract lawsuit from former associates at Avalor Cap"

$DMAA Current Stock Price: $10.46

$DMAA Volatility reflects uncertainty about how effectively strategy converts into measurable outcomes. Cost discipline must coexist with targeted investment. Consistent milestones could shift perception faster than fundamentals alone. In short, this remains an execution‑driven story with meaningful but conditional upside.

$DMAA - Drugs Made In America Acquisition Corp. - 10Q - Updated Risk Factors DMAA flags reliance on third-party digital systems for cybersecurity, limited internal resources for protection or response, and potential for material losses if cyber incidents occur. #CybersecurityRisk #DigitalSystems #MaterialLossPotential #LimitedInternalResources #Third-PartyDependency 🟢 Added 🟠 Removed https://d-risk.ai/DMAA/10-Q/2025-11-18

After Hours Top Gainers PT2 $ASST $DMAA $APLM $DMAAU $CUPR

$DMAA $BGXX https://dmaacorp.com/our-team/

$DMAA SPAC pre-merger speculation. High risk event path. Trading near trust value. Redemption pressure.